Zentalis Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 3.17% of Zentalis Pharmaceuticals Inc. common stock as of June 30, 2026.
NASDAQ
The Walters Group and its principals have increased their beneficial ownership in Zentalis Pharmaceuticals, Inc. to 19.7% of common stock.
NASDAQ
SCHEDULE: 5AM Funds Boost Zentalis Stake to 6.4%
5AM Opportunities II and Master Funds, along with managing members Andrew J. Schwab and Kush Parmar, report a combined 6.4% beneficial ownership in Zentalis Pharmaceuticals, Inc. following an at-the-market offering.
NASDAQ
Barclays PLC has reported a 5.32% beneficial ownership stake in Zentalis Pharmaceuticals Inc., totaling 3,841,449 common shares.
NASDAQ
Millennium Management LLC and affiliates reported a 1.3% beneficial ownership stake in Zentalis Pharmaceuticals, Inc. as of September 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.2% passive beneficial ownership stake in Zentalis Pharmaceuticals Inc. as of June 30, 2025.
NASDAQ
Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, has filed an amended Schedule 13G indicating they no longer hold any beneficial ownership in Zentalis Pharmaceuticals, Inc.
NASDAQ
SCHEDULE 13G/A: Eventide Asset Management and Affiliates Report Full Divestment of Zentalis Pharmaceuticals Stake
Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have filed an amended Schedule 13G indicating they no longer hold any beneficial ownership in Zentalis Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported a 6.28% beneficial ownership stake in Zentalis Pharmaceuticals, Inc. as of December 31, 2024, through a Schedule 13G filing.
NASDAQ
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a passive beneficial ownership of 5.3% in Zentalis Pharmaceuticals, Inc., totaling 3,781,298 shares of common stock.
NASDAQ
SCHEDULE 13G/A: Walters Group Discloses 9.9% Stake in Zentalis Pharmaceuticals
The Walters Group, along with William T. Walters and Susan B. Walters, has filed an amended Schedule 13G, disclosing a beneficial ownership of 9.9% in Zentalis Pharmaceuticals, Inc.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.59% beneficial ownership stake in Zentalis Pharmaceuticals Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Walters Group Files Amended 13G, Disclosing Continued 9.1% Stake in Zentalis Pharmaceuticals
William T. Walters, Susan B. Walters, and The Walters Group have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 6,500,000 shares, representing 9.1% of Zentalis Pharmaceuticals, Inc.'s common stock.
NASDAQ
William T. Walters, Susan B. Walters, and The Walters Group have disclosed a passive beneficial ownership of 7.0% of Zentalis Pharmaceuticals, Inc.'s common stock.